Can topical phenytoin augment the therapeutic efficacy of PUVA against vitiligo? A double-blind, randomized, bilateral-comparison, placebo-controlled study

Journal of Dermatological Treatment

Volumn 22, Issue 2, 2011, Pages 106-108

  Bahmani, Mohammad ^a   Fallahzadeh, Mohammad K ^a   Jowkar, Farideh ^a   Khalesi, Mohammad ^a   Bahri Najafi, Rahim ^a   Namazi, Mohammad R ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN; PLACEBO;

ADOLESCENT; ADULT; CHILD; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PUVA; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; VITILIGO;

ADOLESCENT; ADULT; ANTICONVULSANTS; CHILD; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; PUVA THERAPY; VITILIGO; YOUNG ADULT;

EID: 79952373920     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903501808     Document Type: Letter

References (6)

1. Namazi MR. Neurogenic dysregulation, oxidative stress, autoimmunity, and melanocytorrhagy in vitiligo: Can they be interconnected? Pigment Cell Res. 2007;20:360-363. (Pubitemid 47390122)
2. Namazi MR. Phenytoin as a novel anti-vitiligo weapon. J Autoimmune Dis. 2005;2:11.
3. Goldstein BG, Goldstein AO. Vitiligo. Uptodate 17.2 Online, http://www.uptodate.com/online/content/topic.do?topicKey=dermatol/ 13979&selectedTitle=1~65&source=search-result(accessed 4 Sep 2009).
4. Rezaei N, Gavalas NG, Weetman AP, Kemp EH. Autoimmunity as an aetiological factor in vitiligo. J Eur Acad Dermatol Venereol. 2007;21:865-876. (Pubitemid 47103715)
5. Scheinfeld N. Phenytoin in cutaneous medicine: Its uses, mechanisms and side effects. Dermatol Online J. 2003;9:6.
6. Westerhof W, d'Ischia M. Vitiligo puzzle: The pieces fall in place. Pigment Cell Res. 2007;20:345-359. (Pubitemid 47390114)